A French drugmaker's big bet on a rare muscle disease came up short in the study meant to prove it works.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
Sevasemten, a pill meant to slow muscle damage in people with Becker muscular dystrophy, showed no statistically significant benefit over a placebo in an…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.